Nrx pharmaceuticals presents evidence zyesami™ (aviptadil) helps prevent "cytokine storm" in patients with covid-19

Radnor, pa., july 19, 2021 /prnewswire/ -- nrx pharmaceuticals (nasdaq: nrxp), will present data at the disease control and prevention summit on july 21, 2021 at 10:10 est, via the following link: https://www.terrapinn.com/template/live/landing/a0a4g00001zmpzpuab/10433?utm_source=&utm_medium=landing-page&utm_campaign=-referral&utm_term=referral-marketing&utm_content=pa03744357 nrx pharmaceuticals presents evidence zyesami™ (aviptadil) helps prevent "cytokine storm" in patients with covid-19 the presentation identifies a statistically significant effect of zyesami™ (aviptadil) in preventing the sharp rise in cytokines, commonly associated with mortality in patients with covid-19.
NRXP Ratings Summary
NRXP Quant Ranking